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Indium chloride (In-111) forms a lipid soluble complex when 
chelated to 8-hydroxyquinoline (oxine). Platelets have been 
labeled with the In-111 oxine complex and found to function 
normally. The labeled platelets have been used to study platelet 
kinetics in animals and the role of platelets in pathologic 
processes in man and animals. The 2.8d half-life and high yield 
of gamma photons make it ideal for external imaging. In this 
study, human blood platelets were labeled with In-111 oxine by 
incubation at room temperature, the intracellular location of the 
In-111 determined and the binding sites characterized. The In-111 
oxine complex traverses the platelet membrane and then dissociates. 
The In-111 was found to be concentrated predominantly in the cytoplasm 
and associated primarily with one component of molecular weight 
45,000 dalton. 
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INTRODUCTION 
In recent years, expansion in the utilization of radioactive 
isotopes as diagnostic, therapeutic or investigative agents in medicine 
has been phenomenal. The development of a wide variety of radiopharma¬ 
ceuticals, coupled with a marked advancement in instrumentation, has 
revolutionized research methods, led to a better understanding of some 
pathologic and physiologic processes and produced new diagnostic tests 
that provide information previously unobtainable or obtainable only with 
prohibitive difficulty. 
A widespread and unique research and diagnostic application is the 
use of radionuclides as tracers. In this application, the capability 
of instruments to detect and identify very small quantities of radio¬ 
nuclides is exploited. A molecule, cell, or even an animal can be 
"labeled" with a suitable radionuclide and the movement of the label 
followed within the animal or plant. The fundamental tenet upon which 
radiotracer methodology is based is that the radioactive atoms or 
molecules behave in the same manner as their unlabeled counterparts 
because they are chemically indistinguishable.^ 
In a given study, the choice of the labeling radionuclide is de¬ 
termined by several factors. I!n vivo studies involving humans require 
that a radionuclide be introduced into the body. The nuclide becomes 
an integral component of the body's chemical makeup and its removal 
from the body is regulated by its chemical and physiologic properties 
and behavior. Specifically, the length of time that a radionuclide 
1 
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remains in the body is largely determined by its biologic half-life, 
as well as by the type and energy of the radiation emitted. Gamma 
radiation can penetrate several millimeters or centimeters of tissue 
and can be detected and quantified by external radiation detectors. 
Hence, gamma-emitting radionuclides are usually used for in vivo diagnostic 
tests. Any diagnostic technique involving the use of a radionuclide 
should be done such as to keep the radiation damage to the body minimal. 
This is accomplished by introducing into the body the minimum amount 
compatible with the sensitivity of the detecting instruments that are 
available and with the duration of the study. 
The use of the radiotracer methodology in hematology has been 
extensively applied. The radioassay of tagged blood elements, i.e., 
erythrocytes, leukocytes and platelest, in vitro is done with a regular 
gamma scintillation counter, consisting of a scintillation detector with 
Nal(TI) crystal (of the well type), a scaler, and a pulse-height analyzer. 
The radioassay of labeled blood elements in vivo requires special 
scintillation probes. In some studies the investigator needs only to know 
the activity in a small area of an organ or tissue. Such localization 
is achieved by means of collimators. In this way, only gamma radiation 
coming from certain directions is "seen" by the detector while the radia¬ 
tion that is possibly being emitted by neighboring areas is excluded. 
In other diagnostic tests an investigator may require a measurement of 
the overall activity of an organ that has absorbed the radionuclide. 
The resulting pattern would theoretically show the differential 
distribution of the radionuclide within the organ and can be correlated 
3 
with possible disease processes. This problem was first solved by 
B. Cassen with an instrument called the scintiscanner. With this 
instrument, the area of the body above the organ of interest is 
scanned point-by-point with a narrowly collimated scintillation 
probe. The probe is mounted on a motor-driven carriage that moves at 
a preset speed. The probe moves back and forth along different lines 
over the area of the subject's body which is of interest and thereby 
scans the radioactivity of the underlying organ. The probe is 
mechanically coupled to a readout device which records and visually 
displays the differential distribution of the radioactivity within the 
organ. This record is called a scintiscan, or scintigram. The recording 
device is mounted on a separate carriage that is synchronized with the 
probe-moving carriage. Since the construction of the first scintiscanner, 
considerable progress has been made in the sophistication of scanning 
instruments. Higher degrees of automation which allow speedier operation, 
better resolution (obtained with improved collimation of the probe) , 
contrast enhancement in the scintiscan, and easier and more intelligible 
visual display have all been accomplished. 
The Radiotracer Methodology and Platelets.--Blood platelets are involved 
in many pathological and physiological processes. Their role in many of 
these processes has not been delineated. The investigator can, however, 
utilize the radiotracer methodology to study platelet actions in health 
and disease as well as platelet kinetics. 
Several isotopes have been used as platelet labels, each with some 
shortening. Their half-lives are either too short or too long and the 
2 
emission of their 3-rays or gamma photons is of little use for imaging. 
4 
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Platelets have been labeled jin vitro with P-diisopropyl fluoro- 
51 14 
phosphate (DFP), Cr-sodium chromate and C-serotonin, and in 
32 3 
vivo with P-diisopropyl fluorophosphate, H-diisopropyl fluoro- 
phosphate and with ^C-serotonin. ^ Of these, "’'"Cr-sodium chromate 
is the most extensively used and is currently recommended as the 
most satisfactory labeling agent for platelets by the International 
Panel on Diagnostic Applications of Radioisotopes in Hematology 
(ICSH, 1977).The usefulness of "^Cr, however, is limited. 
These limitations are imposed by its physical characteristics. 
"^Cr labels platelets with low efficiency and hence a large volume 
of blood is required to achieve sufficient platelet-associated 
3 12 ”■ X A 
radioactivity for survival studies. ’ Furthermore, its low yield 
of gamma photons (10% at 320KeV) limits, and even precludes in some 
cases, in vivo visualization of platelet accumulations and distributions 
using a gamma camera.^ ^ The 27.7 d half-life of "^Cr may mean that 
an unnecessary radiation risk exists. Also, some investigators report 
51 31216 
high in vivo elution of Cr. ’ ’ In light of these disadvantages 
associated with the use of ^Cr, an alternative isotope for labeling 
platelets has been sought. 
In 1975 McAfee and Thakur, working at the Hammersmith Hospital, 
London, made an extensive study of both soluble and particulate agents 
17 18 
for labeling of phagocytic leukocytes. ’ The use of particles as 
labels presented several problems. Hence, soluble agents were used 
and of this group only nonpolar lipid soluble chelates labeled cells 
to a significant degree. Several of the lipophilic chelates were 
observed to elute from the cells whereas the In-111 oxine complex and 
5 
the Tc-99m oxine complex did not elute from the cells. The researchers 
showed that labeling by either of these two complexes was nonspecific, 
i.e., it labeled all types of cells. This necessitated cell purifi¬ 
cation before labeling. Such purification has proven to be a most 
difficult technical problem as it is crucial to preserve the viability 
of these labile cells. Gentle centrifugation and pipetting techniques 
must be used and the selection of the proper anticoagulant and labeling 
medium made. No special equipment is needed but practice is essential 
for the success of the method. Then, in 1975, Thakur et al. at the 
Mallinckrodt Institute of Radiology in St. Louis developed the In-111 
oxine (^’^In chloride chelated to 8-hydroxyquinoline) method for leuko- 
19 
cyte labeling. In-111 has a 2.8d half-life and gamma photon energies 
of 173KeV(84%) and 247KeV(94%) making it possible not only to label 
leukocytes but the other various cellular components of the blood with 
3 13 
a gamma-emitting nuclide, and image their distribution in the body. ’ 
The lipophilic complex was found to label leukocytes by passive dif¬ 
fusion and bind to intracellular components without alteration of 
19 
their functional characteristics. 
This technique already has several important clinical applications. 
Granulocytes labeled with the In-111 oxine complex were used for the 
2 15 
scintigraphic visualization of experimentally-induced abscesses. ’ 
Subsequently, the suitability of the In-111 oxine complex as a platelet 
label was evaluated. Platelets labeled with In-111 oxine have been 
found to function normally, have been used to study platelet kinetics, 




Purpose.--The radiotracer method provides a rational approach for 
studying the role of platelets in hemostasis and thrombosis iri vivo. 
However, the method is useful and scientifically valid only if certain 
criteria are met. A suitable label is one that is non-toxic (i.e., 
has no effect on the experimenter or on platelet life-span or function), 
does not elute or transfer from one platelet to another platelet, is 
not metabolized and is not reutilized by megakaryocytes for new 
platelet production after labeled cells have been removed from circula- 
24 
tion. No label that is currently available meets all of these cri¬ 
teria though the non-polar lipophilic chelate of In-111 promises to 
be an "ideal label." But before one can unequivocably state its 
ideality as a platelet label, the above considerations must be addressed 
and several other questions must be answered. In this context, and as 
a first step, this study, which was to determine the intracellular 
location of the In-111 oxine complex, was initiated. 
Platelet Production.—Platelets are produced through a process of 
cytoplasmic fragmentation of large polyploid bone marrow cells called 
megakaryocytes which constitute less than 1% of the nucleated cells 
25 
of normal bone marrow. Megakaryocytes are derived from committed 
progenitor or 'stem' cells which are the progeny of a multipotential 
2 6 
hemopoietic cell. The stem cells are capable of differentiating 
into erythrocytic, granulocytic and/or megakaryocytic cell lines 
. . . 25-28 „   
with appropriate stimulation. Megakaryopoiesis is unique m 
that the megakaryocyte nucleus increases in mass and size with each 
cycle of DNA replication rather than dividing as most other cells do. 
This takes place before maturation and differentiation begin. Thus, 
7 
cells with 2N, 4N, 8N, 16N, 32N, and 64N amounts of nuclear material 
29-31 
are produced during cellular amplification.' Following appropriate 
'enlargement,' the cell then begins to differentiate and mature into 
32 
a 'typical' megakaryocyte. The nomenclature for the morphologic 
states of megakaryocyte maturation is, according to Bessis: 1) baso¬ 
philic megakaryocyte, 2) granular megakaryocyte, 3) platelet-forming 
32 
megakaryocyte, and 4) platelets and bare nuclei. Megakaryocyte 
production in the marrow is presumably regulated by a humoral stimula- 
33 34 38 
tor, thrombopoietin. ’ The time required for the complete 
sequence of megakaryocyte maturation to take place is four-five days 
in man and culminates with the shedding of enucleate, round or 
lentiform, disc-shaped platelets into the circulating blood (Fig. 1) 
The number of platelets released by individual megakaryocytes may 
39,40 
depend on their ploidy value. 
6,41 
After release, two-thirds of the platelets are in circulating 
33 41 43 
blood and one-third in the spleen. * The average life span of 
a platelet in humans is about 10 days and survival is probably age- 
44—46 
dependent rather than random. 
Platelet Morphology.—The expression of platelet functional activity 
in hemostasis is manifested as three fundamental mechanisms: adhesion- 
47-49 
aggregation, contraction and secretion. In order to underscore 
the intimate relationships that exist between platelet structure, 
function and biochemistry, platelet anatomy is divided into four major 
47-49 
zones. The zones and their components are shown in Figure 2. 
The peripheral zone (PZ) acts to receive and transmit stimuli 
which trigger the platelet response and for adhesion and aggregation 
8 
Fig. 1. Discoid platelets. Indentations (arrows) indicate sites 
where channels of surface-connected open canalicular system 
communicate with cell exterior. Taken from J. G. White, 
Am. J. Clin. Pathol., 71 (4), 363 (1979). 
9 
Fig. 2. Diagram summarizing observations made on many cells. Structural 
elements of the peripheral zone include the exterior coat (EC), 
the unit membrane (CM), and a submembrane area containing 
submembrane filaments (SMF). SMF are also included with the 
circumferential band of microtubules (MT) amd microfilaments as 
the three major fiber systems constituting the matrix of the 
sol-gel zone. Also shown are granules (G), dense bodies (DB), 
and mitochondria (M), and the formed organelle zone. Three 
systems of channels are present in the platelet substance, 
including the open canalicular system (CS) continuous with the 
cell surface, the dense tubular system (DTS) associated with the 
circumferential band of microtubules and a Golgi zone (GZ) 
found in about 10% of platelets. Glycogen particle (Gly) are 
usually concentrated in masses in the matrix(l). Taken from 
L. M. Aledort, Semin. Thrombos. Hematol., _2, 136 (1976). 
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reactions. The peripheral zone consists of an exterior coat (EC), 
or glycocalyx, a trilaminar or unit membrane and a submembrane 
region. The glycocalyx is rich in glycoproteins and, as the outer¬ 
most coat of the peripheral zone, acts to mediate platelet-platelet 
and platelet-vessel wall interactions. The middle layer of the 
peripheral zone is a typical trilaminar membrane which provides a 
surface for platelet interaction with arachondonic acid and with 
coagulant proteins. The submembrane region lies directly beneath 
the unit membrane. 
A dense tubular system (DTS) is frequently found interdigiting 
with a surface connected open canalicular system (OCS) to form 
assemblies designated as a membrane complex (MC) . The DTS has been 
shown to be the site of calcium sequestration and for enzymes involved 
in prostaglandin synthesis. Access to the interior of a platelet for 
plasma-borne substances and an egress route for products of the 
release reaction are provided by the OCS. 
The sol-gel zone (SGZ) constitutes the matrix of the platelet 
cytoplasm and consists of several fiber systems which are in various 
states of polymerization. It contains microtubules and microfila¬ 
ments which have been implicated in pseudopod extrusion, internal 
transformation, secretion, production and storage of contractile 
elements and in shape change. 
At least three types of particulates, offering distinctive 
morphology, functional capabilities and biochemical composition 
comprise the organelle zone (OZ) . These are the mitochondria, dense 
11 
bodies and granules. Mitochondria (M) are easily discernible by 
virtue of the plication of their inner membrane into cristae. Dense 
bodies (DB) are storage compartments for substances such as epine¬ 
phrine, (ADP), and serotonin. Dense bodies are identified by their 
intensely opaque content. Granules (G) are the most numerous of the 
organelles and there is increasing evidence in support of a hetero¬ 
geneous granule population. One type of organelle, which has been 
long recognized, contains serotonin, adenosine triphosphate (ATP), 
adenosine diphosphate (ADP), calcium and pyrophosphate. Brenton- 
Gorius and Guichard have demonstrated that some of the organelles 
in platelets resemble peroxisomes found in several other tissues. 
35 
Da Prada et_ ad. have experimentally distinguished two populations of 
granules.One population contains only platelet factor 4 and 
fibrinogen while the other population possesses only acid hydrolases. 
Platelet Function.—Platelets play a pivotal role in the events 
leading to hemostasis. Under physiologic conditions, vascular 
integrity is maintained through the 'collaborative' efforts of 
35 51~ 5 6 
platelets and endothelial cells. ’ The unaltered vascular endo¬ 
thelium is nonthrombogenic, i.e., it does not support platelet 
57 53 
adherence. ’ However, pathologically or traumatically induced 
injury to the endothelium results in the detachment of the covering 
endothelial cells and the consequent exposure of subentothelial 
elements (viz., collagen, basement membrane, microfibrils and elastin) 
59-62 
thereby rendering the vessel wall thrombogenic.' Ordinarily, 
platelets are non-adherent to either endothelium or to other 
platelets, but when platelets in the circulating blood encounter the 
12 
exposed subendothelial elements, primarily collagen, they adher to 
these structures.^^^ Hence, the exposed subendothelial 
elements act at once as agonists and as substrates for platelet 
interaction. The adhesion of platelets to subendothelial structures 
constitutes the primary event in hemostasis. After such adhesion, 
the platelets which are adherent to the subendothelial structures 
undergo a "release reaction," a process which involves shape change 
(Fig. 3), a compacting of the intracellular organelles to the center 
of the platelet, a release of the contents of granules, i.e., 
serotonin, ATP, ADP, acid hydrolases, fibrinogen, vascular permeability 
factor, 6-thromboglobulin, platelet factor 4 and growth factor into 
the extracellular medium via the open canalicular system and the 
formation of prostaglandin endoperoxides, namely thromboxane A^ 
(TXA^) ■ ^ ^ The ADP released from the granule and the thromboxane 
A2 formed by the platelets interact with platelets flowing by the site 
of injury, causing them to undergo a shape change and to release the contents 
of their granules.^ These platelets then adhere to those platelets 
66 
already adherent to collagen and other subendothelial structures. 
These events result in the formation of platelet aggregates.^ 
Aggregation constitutes the second event in hemostasis. Aggregation 
is a reversible process if the concentration of exogenous ADP in situ 
is low. Increasing the concentration of ADP beyond a critical 
threshhold, however, induces irreversible aggregation. ^ There are 
agents besides ADP which are capable of causing aggregation. These 
include: collagen, antigen-antibody complexes, polymerizing fibrin, 
proteolytic enzymes, e.g., thrombin and snake venom extracts, the 
13 
Fig. 3 6a: Shape change in platelets after exposure to adenosine 
diphosphate. Loss of discoid shape to form irregular 
spheres and extension of long pseudopods are shown. 
6b: Internal contraction, platelet from sample exposed to 
adenosine diphosphate. Taken from J. G. White, Am. -J. Clin. 
Pathol., 71 (4), 363 (1979). 

15 
antibiotic ristocetin, etc. The initiating mechanism of these agents 
may differ but aggregation induced by all of them probably proceeds 
through the common mechanism of endogenous ADP release from plate- 
69 
lets. The intrinsic pathway of blood coagulation is activated 
around the platelet mass in a number of ways. Blood coagulation is 
considered by most to be an enzymatic process.*^ This concept has 
received its most complete expression in the cascade sequence for 
blood coagulation (Fig. A). In this conception, each of the blood 
coagulation factors (Table 1) persists as a proenzyme. Each proenzyme 
is converted to an enzyme during the clotting process, except for 
fibrinogen, which is converted to an insoluble fibrin clot that is 
deposited on the platelet mass. Hence, the function of each enzyme 
is that, as it is formed, it activates the proenzyme which succeeds 
it in the coagulation sequence. Platelets participate in clotting by 
providing phospholipids, essential phospholipids, to the coagulation 
process, most notably platelet factor 3.^ Platelet factor 3 appears 
on the platelet surface following platelet aggregation. It is thought 
that platelet factor 3 on the platelet surface provides a catalytic 
surface for an essential coagulation reaction. Activated platelets 
have recently been observed to provide a "catalytic" surface and 
factors VIII, V, I (fibrinogen), and XIII. These substances are 
viewed as intrinsic but "surface" after or during the release 
72 
reaction. 
Platelet Metabolism.--Platelets have an active energy metabolism that 
provides energy for the maintenance of normal structural integrity and 
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Fig. 4. A simplified version of the cascade theory of blood 
coagulation. Taken from C. A. Sibley, "Thrombosis and 
Hematosis Procedures," U. S. Department of Health, 
Education and Welfare, Public Health Service, Center 
for Disease Control, Atlanta, CA. 
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III Thromboplastin, Thrombokinase, Tissue Extract 
IV Calcium 
V Labile Factor, Proaccelerin, Plasma Accelerator Globulin, 
Plasma Ac-Globulin 
VI Not assigned 
VII Stable Factor, Proconvertin, Autoprothrombin I, 
Serum Prothrombin 
VIII Antihemophilic Factor (AHF), Antihemophilic Glovulin (AHG), 
Platelet Co-Factor I, Thromboplastinogen, Antihemophilic 
Factor A 
IX Plasma Thromboplastin Component (PTC), Christmas Factor, 
Platelet Co-Factor II, Autoprothrombin II, Antihemophilic 
Factor B 
X Stuart Factor, Prower Factor, Stuart-Prower Factor, 
Autoprothrombin III 
XI Plasma Thromboplastin Antecedent (PTA), Antihemophilic 
Factor C 
XII Hageman Factor, Surface Factor, Contact Factor, Clot- 
Promoting Factor 
XIII Fibrin Stabilizing Factor (FSF), Fibrin Stabilizing Enzyme, 
Fibrinase, Laki-Lorand Factor 
*Taken from C. A. Sibley. "Thrombosis and Hematosis procedures," U.S 
Department of Health, Education, and Welfare, Public Health Service, 
Center for Disease Control, Atlanta, GA. 
18 
monophosphate shunt (mitochondria), a tricarboxylic acid cycle 
(mitochondria), a gluconeogenesis pathway (mitochondria), an 
73 
Embden-Meyerhof pathway, and a glycolytic pathway (cytosol). 
The mitochondria also participate in the synthesis of lipids, fatty 
acids, phospholipids, amino acids and proteins, despite the absence 
of DNA and ribosomes.^ 
Platelet Dysfunction.—The accepted concept of normal hemostasis in¬ 
corporates the requirements for the integrity of the vessel wall, 
platelets and coagulation factors. Abnormalities which are quanti¬ 
tative and/or qualitative in nature, in any of these three elements, 
can lead to a bleeding diathesis. 
73 
Platelet disorders fall into one of three categories. Thrombo¬ 
cytopenia is the condition of an insufficient number of platelets. 
This condition can be caused by excessive destruction or sequestration, 
or by deficient production and is manifested as superficial bleeding. 
Thrombasthenia and thrombocytopathy describe conditions in which 
platelets persist in their usual number but are abnormal in function. 
Thrombocytopathic conditions are either congenital or acquired. Both 
of these conditions are manifested as deep bleeding. Conditions of 
thrombocytosis and thrombocythemia result from an excessive number of 
platelets. 
EXPERIMENTAL 
Materials and Methods 
Preparation of ^^In-Oxine Complex. —^^In-8-hydroxyquinoline, 
^^In(8-HQ) ^, was prepared according to the method of Scheffel et al.^ 
Briefly, 1.5ml of Indium-111 Chloride (InCl^)(Mediphysics, Inc., 
Emeryville, CA) was placed in a glass test tube. Four-and-a-half 
milliliters of sterile water was added to the tube, followed by 0.2ml 
of 0.3M acetate buffer (pH 5.0). A lmg/ml solution of 8-hydroxy- 
quinoline, (8-HQ)^, in ethanol was prepared by dissolving 5mg of 
8-quinolinol (J.T. Baker, Phillipsburg, N.J.) in 5ml of absolute 
ethanol and lOOpl of the (8-HQ)^ was added to the buffered "'"’^InCl. 
The solution was mixed well by tilting the tube and allowed to 
incubate at room temperature. The '^'*'In(8-HQ)^ complex was extracted 
in approximately 3ml of methylene chloride. The radioactivity of a 
lOpl sample of a 1:10,000 dilution of both the organic and aqueous 
phases was determined using an automatic gamma scintillation counter 
(Gamma 9000 Counting System, Beckman Instruments, Inc., Fullerton, CA) 
with the window set at 150-330KeV. Samples were counted to 6% error 
at 2 standard deviations. Background was determined by counting a 
blank tube. The methylene chloride of the organic phase was then 
evaporated using a 50-70° water-bath. Any residual water in the test 
tube vas evaporated using a stream of nitrogen and the residue was 
dissolved in 100pl of 8-HQ-ethanol followed by 0.3ml of normal saline. 
19 
20 
Preparation of In-Labeled Platelets.—Normal human platelets, 
anticoagulated with citrate phosphate dextrose (CDP) were obtained 
from the American National Red Cross Blood Services, Atlanta region, 
and used within 24 hr of collection. Approximately 8 x 10^ 
platelets were centrifuged for 20 min at 150 rpm (Beckman J-21B, 
JA20 rotor, Beckman Instruments, Inc., Palo Alto, CA) to remove 
contaminating red cells. The platelet-rich supernatant was decanted 
into a 50ml plastic conical tube and recentrifuged for 15 min at 
3000 rpm to obtain a platelet pellet. The resultant pellet was 
washed 3 times in 50ml 0.063M Tris/0.012M citrate/0.10M KC1, pH 6.2 
by resuspension and recentrifugation for 10 min at 3000 rpm. After 
the final wash, the pellet was resuspended in 1ml of the same medium 
and labeled by incubation with approximately 25yl of the ^IntS-HQ^ 
complex at room temperature. In pilot studies, incubation was carried 
out for various time intervals at room temperature. The reaction was 
stopped by the addition of approximately 1ml of Tris/citrate/KCl 
solution (pH 6.2) and immediate centrifugation at 3000 rpm for 5 min. 
To determine the labeling yield, or efficiency, the radioactivity of 
an aliquot of the supernatant and of the platelet pellet was counted. 
The labeled platelet suspension was brought to a final volume of 
approximately 20ml and transferred to a nitrogen cavitation cell 
disruption bomb (Parr Instruments Company, Moline, IL) that had been 
pre-cooled to 4°. Nitrogen was allowed to reach 11501b/in for 30 min. 
Pressure was released to disrupt the platelets and the process 
repeated 3 times. The homogenate was then sonicated (Branson 
21 
Sonifier, Model W-350, Branson Sonic Power Company, Danbury, 
Conn.) at output control setting 5 for two continuous seconds. 
Preparation of Subcellular Fractions.—One ml of platelet homogenate 
was layered onto approximately 11.6ml of a linear 30%-60% sucrose 
gradient in 5mM disodium ethylenediaminetetraacetate (EDTA). The 
gradients were prepared immediately before use using a gradient former 
(Buchler Instruments, Fort Lee, New Jersey). In one experiment, in 
which the mode of incorporation of the radionuclide was being investi¬ 
gated, the gradients were prepared without EDTA. The linearity of 
the gradients was periodically ascertained by refractive index readings 
of 1ml samples using a refractometer (Bausch & Lomb Abbe-3L Refracto- 
meter, Rochester, New York). In a typical experiment, 6 gradients 
were centrifuged simultaneously at 30,000 rpm for 120 min at 5° 
(Beckman L5-50 Ultracentrifuge, Beckman Instruments, Inc., Palo Alto, 
CA). Each fraction was successively removed from the upper surface 
of each gradient using a siliconized pasteur pipette. The particulate 
fractions were diluted one to three-fold with 0.29M sucrose and 
pelleted by ultracentrifugation at 30,000 rpm for 60 min at 5°, giving 
subfractions of these particulate fractions, i.e., X particulate and 
X soluble (Xp and Xs, respectively) where X equals fractions B, D, F, 
and H (Fig. 5). The sedimented subfractions were thoroughly 
resuspended with a glass teflon homogenizer in 0.15M NaCl containing 
2mM imidazole (pH 7.4). The respective fractions and subfractions 
from all 6 gradients were pooled to provide an adequate amount for 
analysis and stored at 4° until analyzed for enzyme activity or 
radioactivity, or both. 
PARTICULATE PHASE (MEMBRANE) 
SOLUBLE PHASE 
PARTICULATE PHASE (MITOCHONDRIA) 
SOLUBLE PHASE 
PARTICULATE PHASE (GRANULAR) 
SOLUBLE PHASE 
PARTICULATE PHASE (CELLULAR DEBRIS PARTIALLY EXPOSED 
SOLUBLE PHASE PLATELETS) 
Fig. 5. Diagram of a typical density gradient separation. See Materials and Methods 
section for details of preparation of platelet homogenate, loading and makeup 
of gradient and conditions for ultracentrifugation. Nine fractions, four 
particulate fractions and five "clear" fractions are designated. 
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Enzyme Determinations.—The following marker enzyme assays were used 
in the characterization of all fractions obtained by differential 
centrifugation of unlabeled platelets (prepared as described above 
except for the incubation of washed platelets with the In-111 oxine 
complex) . Lactate dehydrogenase was used as the marker for the 
cytoplasmic fraction using a Sigma Chemical Co. modification of the 
74 
spectrophotometric method of Wroblewski and LaDue. Isocitric 
dehydrogenase was used as the marker for the mitochondrial fraction.'7"’ 
7 6 
Platelet Factor IV was used as the marker for the granular fraction. 
Comparisons of enzyme activity were made on fractions isolated from 
the same homogenate. Fractions were subject to treatment with 
Triton X-100 or sonication before assaying in order to fully release 
the enzymes. 
Lactate Dehydrogenase (LDH).—The standard incubation mixture for the 
assay of LDH activity contained 0.2mg of reduced nicotinamide adenine 
dinucleotide (NADH), 2.85ml of 0.1M phosphate buffer (pH 7.5), and 
0.05ml of the platelet sample. The mixture was allowed to stand for 
20 min at 15°, followed by the addition of 0.1ml of 0.02M sodium 
pyruvate in 0.1M phosphate buffer (pH 7.5). The reduction of pyru¬ 
vate to lactate is coupled by the oxidation of reduced nicotinamide 
adenine dinucleotide phpsphate (NADP) which was followed spectrophoto- 
metrically in terms of reduced absorbance at 340nm using a Beckman 
Spectrophotometer ACTA MVI. One unit of LDH activity equaled a 
decrease in A^Q of 0.001 per min at 25°. 
Isocitric Dehydrogenase (ICD).—The standard incubation mixture for 
the assay of ICD activity containing 0.3rag of NADP, 2.0ml of L-isocitric 
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acid, trisodium salt, 0.8yM/ml was allowed to stand at 25° for a few 
min. One ml of the platelet sample, pre-warmed to 25°, was added to 
the incubation mixture. This procedure measures absorbance of reduced 
NADP at 340nm following the ICD-catalyzed oxidative decarboxylation 
of L-isocitrate to ketoglutarate. The change in absorbance was 
recorded using a Beckman Spectrophotometer ACTA MVI. ICD values are 
expressed in terms of units/ml. A unit of ICD activity is defined 
as the quantity of enzyme in 1ml serum that will produce lmpM of 
NADP in 1 hr at 25°, pH 7.5. 
Platelet Factor IV (PF4).—A commercially available radioimmunoassay 
kit (Abbott Laboratories, Chicago, IL) was used to estimate PF4. In 
this assay the concentration of antiserum and that of labeled antigen 
were kept constant while the amount of nonlabeled antigen was varied, 
thereby obtaining a standard curve. A 73% saturated ammonium sulfate- 
solution is utilized to separate the bound labeled PF4 from the free 
PF4. A standard amount of ammonium sulfate solution is added and 
vigorously agitated to a mixture of antigen and antiserum, which has 
been allowed to incubate. After a short incubation period, the preci¬ 
pitate is separated by centrifugation. The supernate is discarded 
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and the precipitate is counted to determine the amount of I-PF4 
bound to antiserum. 
G-100 Column Chromatography.--Two ml of labeled cytoplasmic fraction 
(45,000-60,OOOcpm) were applied to 2.6x36cm columns of Sephadex G-100 
(Pharmacia Fine Chemicals, Piscataway, N.J.). All columns were 
equilibrated and eluted at room temperature with 0.05M Tris-HCl buffer 
(pH 7.2) containing 0.15M NaCl. Elution was performed at 11.2 ml/hr. 
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Five ml fractions were collected (LKB UltroRac fraction collector, 
LKB Instruments, Inc., Rockville, MD) and the radioactivity in each 
fraction was determined. For molecular size, MW, estimation of the 
following proteins, supplied in the Calibration Kit (Pharmacia Fine 
Chemicals, Piscataway, N. J.), or obtained as indicated, were used 
for column calibration: ovalbumin, Mw = 45,000 dalton; ribonucléase 
A, Mw = 13,700 dalton; bovine albumin, Mw = 80,000 dalton (Sigma 
Chemical Co., St. Louis, MO); cytochrome c, Mw = 12,384 dalton 
(Sigma Chemical Co., St. Louis, MO); and, dextran blue 2000, Mw = 
2,000,000 dalton (Pharmacia Fine Chemicals, Piscataway, N. J.). The 
void volume was determined by the elution position of blue dextran 2000 
Extraction .--A 25p1 aliquot of the cytoplasmic fraction derived from 
In-111 labeled platelets was added to 1ml Tris/citrate/KCl solution, 
pH 6.2. The mixture was extracted in approximately 1ml of methylene 
chloride. The radioactivity of a 500pl sample of both the organic and 
aqueous phases was determined using a gamma scintillation counter. 
Dialysis.—One ml of the platelet cytoplasmic fraction harvested from 
sucrose gradients prepared from sucrose solutions containing no EDTA 
was added to 0.5ml of 7.5% EDTA and this mixture was dialyzed over¬ 
night at room temperature against 100ml distilled water. Aliquots from 
inside and outside of the dialysis tubing, as well as the tubing itself 
were counted for radioactivity. 
Electron Microscopy.—Fractions prepared for electron microscopy were 
not stored. After collection from the gradient tube, the samples were 
immediately fixed in cold 2% Glutaraldehyde in 0.2M S-collidine buffer 
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for 1 hr. The samples were postfixed in 1% OsO^ in 0.2M S-collidine 
buffer for 45 min. The samples were then stained en bloc with 
saturated uranyl acetate in 70% ethanol for 1 hr and dehydrated in 
graded ethanols. The samples were embedded in an epoxy resin. 
Ultrathin sections, prepared with an LKB Ultratome, were placed on 
bare copper grids and examined in Phillips electron microscope. 
Protein Determination.—Estimations of protein content were made 
using the Bio-Rad protein assay procedure and using bovine serum 
albumin as the standard protein.^ 
RESULTS 
Subcellular Fractionation Studies.—Human platelet homogenates were 
fractionated by differential centrifugation on continuous 30% to 60% 
sucrose gradients. Nine fractions were separated by this technique; 
four particulate fractions and five "clear" fractions. The appearance 
of a typical gradient and the scheme for (sub)fractionation is 
presented diagramatically in Figure 5. Particulate fractions were 
defined by morphological and enzymatic analysis. 
Electron micrographs of the particulate material from (subtrac¬ 
tions Dp, Fp and Hp are presented in Figures 6,7, and 8, respectively, 
and a description of the various subcellular organelles identifiable 
in each (sub)fraction is presented in the legends to the figures. 
Although all fractions contained some contaminating materials, each 
contained a predominance of one type of organelle. The majority of 
organelles in (sub)fraction Dp are mitochondria. Numerous mitochon¬ 
drial fragments are also identifiable in this fraction. Subfraction 
Fp had an abundance of granular material. Electron microscopy revealed 
(sub)fraction Hp to contain partially exploded platelets, unexploded 
platelets and cellular debris. 
The enzyme distributions found are shown graphically in Figures 
9 and 10. Lactate dehydrogenase activity was found almost exclusively 
in fraction A. Only small amounts were found in (sub)fractions 2 and 3, 
and virtually no activity at all was found in the remaining fractions 
and (sub)fractions. Lactate dehydrogenase is the accepted marker 
27 
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Fig. 6. Electron micrograph of mitochondrial (sub)fraction, Dp. 
Mitochondrial fragments predominate but there are some 
intact mitochondria (M), discernible by the plication of 
their inner membranes into cristae. 
29 
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Fig. 7. Electron Micrograph of granular (sub)fraction, Fp. 
Platelet granules are recognized as electron-dense centers 
surrounded by a single membrane. 
31 
32 
Fig. 8. Electron micrograph of (sub)fraction containing 







































Fig. 9a. Distribution of 30%-60% linear sucrose gradient of 
lactate dehydrogenase (LDH) activity. Relative specific 
activities are plotted versus percentage of total protein 
97 
recovered according to Broekman e_t al. Subfractions 






























Fig. 9b. Distribution in 30%-60% linear sucrose gradient of 
isocitric dehydrogenase (ICD) activity. Relative 
specific activities are plotted versus percentage of 
total protein recovered according to Broekman e_t al. 
Subfractions from one homogenization procedure were 















Fig. 10. Distribution in 30%-60% linear sucrose gradient of platelet 
factor 4 activity. The details of the preparative 
procedure are described in the Materials and Methods 
section. The results of one experiment are plotted. 
Platelet factor 4 activity is expressed as Ng/ml fraction. 
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enzyme for the cytoplasm. Isocitric dehydrogenase, a mitochondrial 
marker enzyme, had a diffuse range of activity. Most of the 
isocitric dehydrogenase activity was found in the cytoplasmic frac¬ 
tion. However, of the particulate (subtractions, isocitric dehydrogenase 
activity was contained in (sub)fraction D!, the mitochondrial 
(sub)fraction. 
Platelet factor 4 activity peaked sharply in the subfraction shown 
by electron microscopy to be granular material, (sub)fraction Fp. 
Lesser amounts of PF4 activity were found in fractions E and G (Fig. 10). 
Uptake of In-111 Oxine by Platelets.—The effect of time of incubation 
on uptake of In-111 by human platelets was considered. The optimal 
labeling time was determined to be 10 min. This 10 min incubation 
period afforded a labeling efficiency of about 65%. A 10 min incubation 
period was used in all subsequent experiments. 
Subcellular Distribution of In-111.—Platelets were incubated with the 
In—111 oxine complex for 10 min, fractionated and the location of the 
radioactivity determined. The distribution is shown in Figure 11a and 
percentage distribution is shown in Figure lib. Fifty-three percent 
of the radioactivity was found in the cytoplasmic fraction; 17% is 
associated with the membrane fraction; 2% is associated with the 
mitochondrial fraction; 6% is associated with the granular fraction; 
and 6% is associated with partially exploded and intact platelets. 
Fractions B, D, F and H, according to the fractionation scheme in 
Figure 1, were centrifuged a second time, giving (sub)fractions of 
these particulate fractions. These (sub)fractions were designated 
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(Sub)Fraction 
Fig. 11a. Distribution of In-111 among subcellular organelles in 














Fig, lib. Percentage distribution of In-111 among subcellular 
organelles in sucrose gradient. 
40 
X particulate and X soluble (Xp and Xs, respectively) where X 
equals B, D, F and H, respectively. The distribution of the 
radioactivity between the particulate and soluble phases of these 
fractions is enumerated below. Four percent of the radioactivity in 
the membrane (sub)fraction is associated with the sedimentable 
phase; 96% of the radioactivity in the membrane fraction is associated 
with the soluble phase. Twelve percent of the radioactivity in the 
mitochondrial (sub)fraction D is associated with particulate material; 
88% of the radioactivity in this (sub)fraction is associated with 
soluble components. Forty-five percent of the radioactivity in the 
granular (sub)fraction F is associated with particulate material; 
55% of the radioactivity in this (sub)fraction is associated with 
soluble components. Fifty-four percent of the radioactivity in the 
intact and partially exploded platelet (sub)fraction H is associated 
with particulate material; 46% of the radioactivity in this (subtrac¬ 
tion is associated with soluble components. The remaining 17% of the 
radioactivity was found in the intermediate "clear" fractions. 
Molecular Weight Determinations.--Chromatographic studies were initiated 
to provide a molecular weight estimation(s) of the cytoplasmic 
component (s) with which In-111 was associated. A typical chromatogram 
is shown in Figure 12. The first component was eluted in the total 
volume and corresponded to a large Mw molecule. The first major peak 
of radioactivity was eluted at a position corresponding to a Mw of 
approximately 46,000 dalton. The second major peak of radioactivity 
emerged at a position corresponding to a Mw of approximately 30,000 
dalton. A much smaller fourth peak was eluted with components of low 
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Tube Number 
Fig, 12. Elution profile of In-111 labeled platelet cytoplasmic 
components chromatographed on Sephadex G-100. The results of 
a single experiment are shown. The columns were eluted at 
. 25C with 0.05M Tris-HCl buffer, pH 7.2, containing 0.15M 
NaCl and calibrated by determining the elution volumes of 
certain enzymes. Five milliliter fractions were collected and 
the radioactivity in each determined as described in Materials 
and Methods section. The peaks were eluted corresponding to 
the following Mw: a: 155,000 dalton; 6: 46,000 dalton; 
y: 30,000 dalton; 6: total volume. 
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Mw. In this procedure more than 83% of the counts were removed. 
Extraction.—The extraction experiments were done to determine if 
the In-111 remained chelated to the carrier 8-hydroxyquinoline after 
the In-111 oxine complex had traversed the platelet membrane. An 
aliquot of the cytoplasmic fraction, derived from In-111 labeled 
platelets, was extracted in methylene chloride. The extraction 
procedure yielded free 8-hydroxyquinoline. 
Dialysis.--The dialysis experiment was performed in an effort to 
characterize the type of association, e.g., covalent or electro¬ 
static, between In-111 and the cytoplasmic components with which 
In-111 is associated. More than 86% of the radioactivity associated 
with cytoplasmic components was dialysable. 
DISCUSSION 
The findings reported in this paper confirm previously reported 
findings that human platelets can be labeled with In-111 oxine with 
13 
high labeling efficiency. In this study, a mean labeling efficiency 
of 65% was achieved. This represents a significant improvement over 
the 2-5% labeling efficiency that is achieved with "’^Cr-sodium chro¬ 
mate, which has recently been recommended by the International Panel 
on Diagnostic Applications of Radioisotopes in Hematology as the 
8 13 
most satisfactory labeling agent for blood platelets. ’ In-111 
labels platelets with such a relatively high efficiency probably 
because of the lipid solubility of the 8-hydroxyquinoline carrier 
molecule, which facilitates the movement of the min^+ ions across 
the cell lipid bilayer. Indium-111 forms a saturated (3:1) complex 
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with oxine similar to that of a (3:1) oxine: iron complex. A 
3:1 oxine: Indium-111 complex is neutral and very lipid-soluble and 
in keeping with the Davson-Daniellie principle (which states that the 
ease of penetration of a lipophilic complex increases with increasing 
lipophilic character), penetrates the lipid bilayer of a platelet 
membrane relatively easily and is thus able to label platelets with a 
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high efficiency. The results of this study show that once the In-111 
oxine complex has traversed the platelet membrane, indium is displaced 
( from the complex and subsequently binds to cytoplasmic components. 
80 8] 
This finding is in agreement with that of other investigators. ’ The 
displacement of the indium from the complex is probably due to the low 
estimated stability constant of the In-111 oxine complex, which is 10^3^ 
43 
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It is generally accented that platelets are labeled with In-111 
via a non-energy requiring mechanism.^^ However, the precise 
mechanism of uptake of the In-111 oxine complex by platelets is not 
yet agreed upon. This question was not approached in this study 
though several possible explanations have been offered. 
Hwang investigated the mode of interaction of the In-111 oxine 
with liposomes by examining the perturbed angular correlation produced 
by the interaction of the In-111 oxine complex with the lipid bilayer 
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of liposomes. Liposomes are aqueous compartments enclosed by a li¬ 
pid bilayer and have been used extensively as models for biologic 
8 3 
membranes. The ability of liposomes to encapsulate materials make 
them ideal systems for the study of possible interactions of the In-111 
oxine complex with membrane lipid bilayers and with cytoplasmic compo¬ 
nents of a cell. The data in this investigation was obtained in the 
following way. When two gamma rays from a radioactive nucleus are 
emitted in cascade and are detected with a coincidence spectrometer, 
the coincidence counting rate W(9,t) may depend strongly on the angle 
9 between their directions of propagation. The angular correlation 
can be perturbed by the interaction of external fields with the nucleus 
in the intermediate state. Hence, the angular correlation of the 
173-247KeV gamma ray cascade in '*'"*"'*'Cd, following the decay of ^^In, 
can be perturbed by the interaction of the nuclear moments in the 
intermediate state with fluctuating external fields. Hence, a study 
of the perturbed angular correlations of gamma rays from the 
radioactive nuclei can then provide a measure of the nuclear relaxation 
time of the molecules to which the emitting nuclei are bound. In this 
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study, Hwang reports observations of the effects of molecular conforma¬ 
tion on the angular correlation pattern of gamma rays following the 
decay of In when the isotope interacts with binding sites of mole¬ 
cules in the lipid bilayer of liposomes and the entrapped chelating 
agent, nitrilotriacetic acid. This study showed that the In-111 
oxine complex diffuses through the lipid bilayer of the liposomes 
and subsequently transfers the ^^In^"*" ions to the chelating agent, 
nitrilotriacetic acid, which is enclosed in the liposomes. The 
transport of the ^^In^+ ions through the lipid bilayer was found to 
be governed by the binding constants of the ions to nitrilo¬ 
triacetic acid on both sides of the membrane as well as by the exchange 
rates of ^^In^+ ions from nitrilotriacetic acid to 8-hvdroxyquinoline. 
The In-111 oxine complex was observed to be exchanged from one lipo¬ 
some to another. A model was proposed in which the In-111 oxine 
complexes which are embedded in the lipid bilayer are in a dynamic 
equilibrium between non-diffusible and diffusible forms. By analogy, 
the In-111 oxine may diffuse rapidly across the platelet peripheral 
zone, which consists of an exterior coat of glycolipids, a typical 
trilaminar membrane and a submembrane region, with subsequent 
dissociation of the In-111 oxine complex and binding of the ^In^+ 
ions to the cytoplasmic components of the platelet. 
An alternative explanation which accounts for the high efficiency 
labeling of platelets with In-111, but one that has not been 
investigated, is that the uptake of the In-111 oxine complex is through 
an open-canalicular system mediated process of "endocytosis." 
Endocytosis is a general term that refers to the process by which 
cells ingest extracellular materials by trapping them within the inward 
84 
foldings of their membrane. The inward foldings with the trapped 
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materials pinch off from the surface to form intracellular vesicles. 
Endocytosis has a nutritional role and was first observed in macro¬ 
phages and other phagocytic cells. Blood leukocytes have been 
31 
labeled with I-iodide through a process of "piggyback" phagocytosis 
whereby the radioactive iodide is incorporated as nonradioactive 
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particles become engulfed. ’ Whether or not platelets have 
phagocytic capabilities was a matter of controversy for some time. 
It would be unlikely that a process of endocytosis would account for 
the labeling of platelets with In-111 if they didn't have phagocytic 
capabilities. Recently, however, particulate substances, i.e., thoro- 
trast, latex and lioid, -have been identified ultrastructurally within 
the channels of the open canalicular system or within platelet 
vacuoles.^ ^ Additionally, Hovig and Grottum have found lipid 
particule in sealed off vacuoles as well as in ruthenium red-stained 
89 
channels of the open canalicular system. More convincing evidence 
in support of platelets having phagocytic capabilities has been offered 
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by Lewis, Maldanado and Mann. These investigators found that latex- 
containing vacuoles also contained acid phosphatase within 60 min 
which infers that a phagolysosome had formed. In view of this 
evidence in favor of phagocytic properties for platelets, endocyto¬ 
sis is a plausible mechanism whereby In-111 is taken up by platelets. 
A third possible explanation to account for the uptake of the 
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In-111 oxine complex by platelets is that a component of the complex 
binds to a specific receptor on the cell surface, as opposed to other 
cell surface entities which engage any opportunistic foreign molecules. 
Such a process of receptor-mediated endocytosis would allow non- 
phagocytic cells to use endocytosis to internalize molecules which have 
been bound to these receptors. Several systems have in fact been 
identified in which non-phagocytic cells utilize a process of receptor 
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mediated endocytosis to internalize extracellular materials. 
Receptor mediated endocytosis of transferrin has been demonstrated 
91 
for erythroblasts and for reticulocytes. Hence, that platelets 
have not been shown unequivocally to possess phagocytic capabilities 
does not preclude the feasibility of an endocvtotic mechanism for the 
uptake of In-111 oxine. 
Blood platelets are extremely labile cells and their viability, 
or functional integrity, is easily compromised. Hence, one is ulti¬ 
mately assured of a high labeling efficiency only if a balance is 
reached between optimal labeling conditions and guidelines for least¬ 
damaging in vitro handling of platelets. Achieving such a balance 
can be a touchy situation. For instance, several investigators 
suggest that labeling of platelets with radioactive indium must 
perforce be carried out in a plasma-free medium if one is to avoid 
successful competition by plasma transferrin with 8-hydroxvquinoline 
111 3+ 3 92 
for binding with In ions. ’ The estimated stability constant 
for the In-111 oxine complex is approximately 10^, whereas the 
estimated stability constant for the In-111 transferrin complex is 
30 20 
much greater, 10 ’ . Since the stability constant of the In-111 
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transferrin complex is 20 powers of 10 greater than the stability 
constant for the In-111 oxine complex, these investigators argue 
that any transferrin in the labeling medium would substantially 
reduce the In-111 platelet labeling efficiency. On the other hand, 
it is equally well established that plasma is necessary to preserve 
13 
platelet viability. These investigators showed that essential para¬ 
meters of normal platelet function and metabolism are changed when, 
if at any time during in vitro handling, the platelets are deprived 
of a plasma environment. In this study, platelets were labeled in 
autologous plasma. Further work is needed to isolate the factor 
or factors in plasma that preserve platelet viability but in the 
meantime it was preferable to maintain platelet viability though it 
meant achieving relatively lower labeling efficiencies. 
In the same vein, a "mild" homogenization procedure was sought, 
i.e., one that would disrupt all platelets and yield intact sub- 
cellular organelles. Techniques for disrupting platelets have included 
19 80,81 94 93 
freezing and thawing, sonication, pestle and blender. ’ ’ ’ ’ 
Following homogenization, isolation of subcellular organelles has been 
achieved using differential centrifugation alone and with discontinuous 
13 78-80 
or continuous gradients. ’ 1 In this study, a modification of the 
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method of Broekman et_ a_l. was used. This method describes the use 
of a nitrogen decompression technique for disrupting human platelets 
and differential centrifugation on continuous gradients for separation. 
They report a more efficient separation of subcellular particulates 
than heretofore shown. In this study, the effectiveness of the homo¬ 
genization process and the results of ultracentrifugation were assessed 
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by electron microscopic examination of the isolated organelles and by 
a comparison of the enrichment of various marker enzymes and of platelet 
factor 4 activity in the fractions. The results showed good separation 
of the cellular components based upon the following reasons. 
Lactate dehydrogenase (LDH) is the accepted marker for the cytosol. 
LDH activity was almost exclusively present in the soluble portion of 
the platelet homogenates. The remaining activity was found in a broad 
peak which corresponded to protein distribution. These findings 
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correlate closely with those of Broekman e_t aT. and Day e_t al. ’ 
The question arises as to the origin of the soluble components. It was 
determined that the degree of platelet disruption was good based on the 
small degree of solubilization of lactate dehydrogenase and by the presence 
of only a few intact platelets. Invariably, there was some amount of 
organelle disruption during tissue homogenization and low levels of 
disruption could conceivably contribute significantly to the cytoplasmic 
fraction. However, numerous intact organelles were observed and the 
solubilization of marker enzymes was small. Hence, it can be concluded 
that while the soluble portions released by damaged organelles did 
contribute to the cytoplasmic fraction, contribution was of such a degree 
as to not invalidate the conclusions drawn from this study. 
The marker generally used for mitochondria is succinic dehydrogenase, 
, . . , , , ,Tr,n. , , ... 90,99,100 but isocitric dehydrogenase (ICD) has also been employed. 
These enzymes are located in the matrix of the mitochondria.'"^ ICD 
activity was found primarily in the cytoplasmic fraction, indicating 
that mitochondrial disruption was relatively extensive. However, ICD 
of the particulate fractions activity peaked in that fraction, identified 
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by electron microscopy to contain numerous mitochondrial fragments and 
a few intact mitochondria. 
Based on morphological data, fraction F (Fig. 5) was identified as 
the granular fraction. Evidence for a granule population that contains 
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platelet factor 4 has been provided by Broekman e_t al. Accordingly, 
platelet factor 4 activity peaked in the granular fraction F. Some 
platelet factor 4 activity was found in the other fractions. This could 
be because some PF4 had been released from disrupted granules or because 
PF4 is in fact associated with different density intact granules in these 
fractions. 
Having identified each of the gradient fractions it was possible 
to name the fraction with the most radioactive indium. The results 
of the fractionation experiments clearly showed that, after 10 minutes 
of incubation with the In-111 oxine complex, most of the radioactivity 
is in the cytoplasmic fraction of the platelets. This finding 
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corroborates by a different method the findings of Hawker et_ aL. As 
much as 53% of the radioactive indium was recovered from the cytoplasmic 
fraction. Of the remaining activity, about 17% is associated with the 
membrane fraction, about 2% is associated with the mitochondrial fraction, 
about 6% is associated with the granular fraction, and about 6% is 
associated with the intact platelets and partially exploded platelets. 
The remaining 17% of the radioactivity was recovered from the intermediate 
"clear” areas according to the fractionation scheme in Figure 1, probably 
due to contamination incurred during collection of the fractions. 
In the Materials and Methods section a procedure is described whereby 
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the particulate fractions B, D, F and H, according to the fractionation 
scheme in Figure 1, are centrifuged a second time, giving subfractions 
of these particulate fractions. These subfractions have been designated 
X particulate and X soluble (Xp and Xs, respectively) where X equals 
B, D, F and H, respectively. Hence, the distribution of the radioactivity 
between the particulate and soluble phases of each fraction should be 
considered. This data was provided by counting aliquots of the particu¬ 
late and soluble phases of each fraction individually. The results of 
this experiment showed that, overall, most of the activity is associated 
with the soluble phase of each fraction. Only about 4% of the radio¬ 
activity in the membrane fraction is associated with sedimentable 
materials; likewise, only 12%, 45% and 54% of the radioactivity in the 
mitochondrial, granular and intact platelet fractions, respectively, 
is associated with particulate material. 
One may again question the origin of the soluble components in the 
cytoplasmic fraction. Results of enzymatic and electron microscopic 
analysis of each fraction in this study indicate that the origin of 
the soluble components in the cytoplasm is cytoplasmic. Several other 
investigators provide indirect evidence that radioactive indium in the 
cytoplasmic fraction is in fact associated with "true" cytoplasmic 
components. Thakur et^ al. report that when In-111 labeled platelets 
are exposed to strong release-inducing agents, e.g., thrombin, ADP 
and collagen, less than 4% of the In-111 was lost and that the uptake of 
the In-111 oxine complex by thrombin degranulated platelets was similar 
2 
to that observed with intact platelets. Also, Joist et^ al. found no 
difference in the aggregability of In-111 labeled platelets with that 
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of unlabeled platelets. These pieces of evidence indirectly provide 
confirmation that radioactive indium is not associated with releasable 
granular constitutents. The association of In-111 with "true" 
cytoplasmic components is further borne out by the low level of 
radioactive indium found in fractions with morphologically intact 
mitochondria and membrane structures. 
Subsequent efforts were extended to determine if, once inside the 
platelet, the In-111 complex dissociates. Accordingly, an aliquot of 
the cytoplasmic fraction derived from labeled platelets was extracted in 
methylene chloride. About 96% of the radioactivity was extractable, 
suggesting that not all of the oxine remains bound to In-111. The next 
logical step, then, was to characterize the components in the cytoplasm 
with which the indium was associated. The results of gel filtration 
indicate that the radioactivity is associated with primarily one 
cytoplasmic component with a molecular weight of approximately 46,000 
dalton. The data further indicated the presence of additional compo¬ 
nents capable of an association with In-111. The molecular weights of 
these components were estimated to be 15,000 dalton and 150,000 dalton. 
It should be noted that the apparent molecular weights of these components 
may not be accurate enough to identify the components. 
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CONCLUSION 
From this study, it is possible to conclude: (a) the In-111 
oxine complex labels human blood platelets efficiently, and (b) once 
inside the platelet the In-111 oxine complex probably dissociates 
with a subsequent association of the ^^In^"*" ions to cytoplasmic 
components. 
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